1. Scrip
  2. >>Business

Core Global Portfolio Drives Takeda Despite Pockets Of Weakness

Entyvio Solid But Hematology More Challenging

 
• By Ian Haydock

Japanese firm raises full-year forecast for core operating profit on continued growth for global brands, despite US recall and hematology pressures.

Takeda Tokyo HQ entrance
Takeda Pleased With Post-Shire Progress • Source: Takeda

"Overall, we are very pleased with our progress. The [Shire PLC] integration is on track but not finished," declared Takeda Pharmaceutical Co. Ltd. CEO Christophe Weber at the company's fiscal second quarter results briefing.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Europe Pharma Heavyweights Call For Higher Drug Prices At Home

 
• By Kevin Grogan

Sanofi's Paul Hudson and Novartis's Vas Narasimhan claim that while Europe is home to some of the most important biopharma companies in the world, its position is in jeopardy.

Galapagos Chief Exec Stoffels Leaving, While Firm Names Spinout’s CEO

 
• By Mandy Jackson

Paul Stoffels, the J&J research veteran who helmed Galapagos during a crucial period, will retire upon the appointment of a new CEO as the company continues its latest transformation.

MetaVia’s ‘Safe’ Obesity Drug Resonates With Analysts, But Not Investors

 
• By Joseph Haas

The biotech reported Phase I multiple-ascending dose data for its obesity drug for the second time in a week, but its safety and tolerability do not offset concerns about relatively unimpressive weight reduction.